Burke PA - Search Results

1

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.

DeNardo SJ, Burke PA, Leigh BR, O'Donnell RT, Miers LA, Kroger LA, Goodman SL, Matzku S, Jonczyk A, Lamborn KR, DeNardo GL. DeNardo SJ, et al. Among authors: burke pa. Cancer Biother Radiopharm. 2000 Feb;15(1):71-9. doi: 10.1089/cbr.2000.15.71. Cancer Biother Radiopharm. 2000. PMID: 10740655

2

Combined modality radioimmunotherapy. Promise and peril.

Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Burke PA, et al. Cancer. 2002 Feb 15;94(4 Suppl):1320-31. doi: 10.1002/cncr.10303. Cancer. 2002. PMID: 11877763 Free article.

3

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Burke PA, et al. Cancer Res. 2002 Aug 1;62(15):4263-72. Cancer Res. 2002. PMID: 12154028

4

Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.

Leigh BR, Burke PA, Hong AM, O'Donnell RT, Howell LP, Miers LA, DeNardo GL, DeNardo SJ. Leigh BR, et al. Among authors: burke pa. Cancer Biother Radiopharm. 1999 Apr;14(2):113-9. doi: 10.1089/cbr.1999.14.113. Cancer Biother Radiopharm. 1999. PMID: 10850294

5

Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.

Winthrop MD, DeNardo SJ, Albrecht H, Mirick GR, Kroger LA, Lamborn KR, Venclovas C, Colvin ME, Burke PA, DeNardo GL. Winthrop MD, et al. Among authors: burke pa. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3845S-53S. Clin Cancer Res. 2003. PMID: 14506182

6

Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.

DeNardo SJ, Yao Z, Lam KS, Song A, Burke PA, Mirick GR, Lamborn KR, O'Donnell RT, DeNardo GL. DeNardo SJ, et al. Among authors: burke pa. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3854S-64S. Clin Cancer Res. 2003. PMID: 14506183

7

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL. DeNardo SJ, et al. Among authors: burke pa. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s. doi: 10.1158/1078-0432.CCR-1004-0013. Clin Cancer Res. 2005. PMID: 16203820

8

Antiangiogenic agents and their promising potential in combined therapy.

Burke PA, DeNardo SJ. Burke PA, et al. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):155-71. doi: 10.1016/s1040-8428(01)00115-9. Crit Rev Oncol Hematol. 2001. PMID: 11418313 Review.

9

Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.

Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW, De Nardo SJ. Burke PA, et al. Int J Oncol. 2006 Jul;29(1):49-55. Int J Oncol. 2006. PMID: 16773184

10

Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.

Albrecht H, Burke PA, Natarajan A, Xiong CY, Kalicinsky M, DeNardo GL, DeNardo SJ. Albrecht H, et al. Among authors: burke pa. Bioconjug Chem. 2004 Jan-Feb;15(1):16-26. doi: 10.1021/bc030018+. Bioconjug Chem. 2004. PMID: 14733579

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters